Synlogic

Synlogic, Inc. engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on August 28, 2017, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Synlogic, Inc. is a biopharmaceutical company which engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on December 20, 2007 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan, M.B. Ch.B., Synlogic's President and Chief Executive Officer, and other...

Synlogic to Present at Upcoming Virtual Banking Conference

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q3 2020 Results - Earnings Call Transcript

Shares of Synlogic (NASDAQ:SYBX) moved higher by 10.11% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 7.69% year over year to ($0.36), which beat the estimate of ($0.47).

Recap: Synlogic Q3 Earnings

CAMBRIDGE, Mass., Nov. 5, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial results for the third quarter ended Sept. 30, 2020, and provided an update on programs...

Synlogic Reports Third Quarter 2020 Financial Results and Provides Business Update

CAMBRIDGE, Mass., Oct. 27, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its third quarter 2020 financial results before the market opens on...

Synlogic Announces Third Quarter 2020 Conference Call & Webcast

CAMBRIDGE, Mass., Oct. 22, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present a poster on SYNB8802, an investigational Synthetic Biotic medicine for the...

Synlogic Presents Preclinical Data on SYNB8802 for Enteric Hyperoxaluria at American Society of Nephrology (ASN) Kidney Week 2020

CAMBRIDGE, Mass., Sept. 14, 2020 /PRNewswire/ -- Synlogic, Inc.

Synlogic Appoints David Hava, Ph.D., as Chief Scientific Officer

CAMBRIDGE, Mass., Sept. 8, 2020 /PRNewswire/ -- Synlogic, Inc.

Synlogic to Present at Upcoming Virtual Banking Conferences

Genius Brands

OrganiGram Holdings Inc.

Waitr Holdings Inc

With a low capital cost and solid growth potential, many investors prefer to invest in penny stocks. Here are the top stocks to buy this year.

7 Top Stocks Under $5

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q2 2020 Results - Earnings Call Transcript

CAMBRIDGE, Mass., July 30, 2020 /PRNewswire/ -- Synlogic, Inc.

Synlogic Announces Promotion of Antoine 'Tony' Awad to Chief Operating Officer and Additions to Leadership Team

CAMBRIDGE, Mass., July 28, 2020 /PRNewswire/ -- Synlogic, Inc.

Synlogic Announces Second Quarter 2020 Conference Call & Webcast

CAMBRIDGE, Mass., June 1, 2020 /PRNewswire/ -- Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the publication in Nature Communications of preclinical data supporting its first...

Publication in Nature Communications Highlights the Preclinical Development of SYNB1891 and its Potential as a Dual Innate Immune Activator to Stimulate an Immune Response in Difficult to Treat Tumors

CAMBRIDGE, Mass., May 21, 2020 /PRNewswire/ -- Synlogic (Nasdaq: SYBX) announced today that the company will host a Virtual R&D Event at 12:30 pm ET on Wednesday, May 27th, 2020. The event will provide an in-depth review of Synlogic's Synthetic Biotic platform and programs for the...

Synlogic to Host Virtual R&D Event

CAMBRIDGE, Mass., May 21, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the termination of its collaboration with AbbVie, a global, research-based...

Synlogic Announces Termination of AbbVie Collaboration Agreement

Synlogic: A Clinical-Stage Biopharma With A Good Risk/Reward Ratio

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q1 2020 Results - Earnings Call Transcript

Shares of Synlogic (NASDAQ:SYBX) rose 2.7% in pre-market trading after the company reported Q1 results.

Recap: Synlogic Q1 Earnings

AvroBio Inc

Fate Therapeutics

Kiniksa Pharmaceuticals Ltd

Mersana Therapeutics

Novocure

Orchard Therapeutics plc - ADR

Tcr2 Therapeutics

The COVID-19 pandemic has changed normal operations for companies across the world as they cope with resource limitations, health precautions and other challenges.

What Wedbush Is Watching in Biotechs Amid Coronavirus Crisis

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q4 2019 Results - Earnings Call Transcript

As of late, it has definitely been a great time to be an investor in Synlogic.

Will Synlogic Continue to Surge Higher?

Compugen

Glu Mobile

GameStop

Groupon

Interpace Diagnostics

Meet Group

RTI Surgical

Zynga

With stocks at all time highs and after the Dow rose more than 22% and the S&P 500 rose over 28% in 2019, many investors have yet to make many changes in the portfolios for what could be another solid 2020.

10 Stocks Trading Under $10 With Massive Upside Potential in 2020

As of late, it has definitely been a great time to be an investor Synlogic

Can The Uptrend Continue for Synlogic?

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q3 2019 Results - Earnings Call Transcript

Synlogic (SYBX) discontinues the development of its early-stage pipeline candidate, SYNB1020, for the treatment of hyperammonemia, following disappointing study results.

News for Synlogic Stock (SYBX)